RxDoctor Payments Data

Nichole Fleming, PA

Physician Assistant · Austin, TXNPI 1871998518

Payments from drug & device makers

$4,735in general payments, 2019–2025

Across 242 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$924
  • AbbVie$795
  • Johnson & Johnson$353
  • Celltrion USA Inc.$269
  • Bristol Myers Squibb$268
  • Takeda Pharmaceuticals U.S.A., Inc.$241
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$4,69399%
  • Education$431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,735 in reported general payments places this provider in the 85th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$14,604
Medicare patients
131
Services billed
146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin12$45,637
LinzessLinaclotide23$32,160
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates127$7,620
Omeprazole218$3,537
Esomeprazole Magnesium47$1,930
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg47$1,089
Pantoprazole Sodium38$443
Spironolactone12$313
Dicyclomine Hcl12$298
Nortriptyline Hcl18$199
Ondansetron OdtOndansetron14$144
Ondansetron Hcl13$56

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$233$45,63712 claims
AbbVieLinzess$795$32,16023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →